NasdaqGS:XERSPharmaceuticals
How Xeris Biopharma’s Shift Toward Profitability and Pipeline Maturity Will Impact Xeris (XERS) Investors
In December 2025, commentary highlighted Xeris Biopharma’s shift from a survival-stage biotech to an emerging profitable specialty-pharma platform, supported by three marketed products, a maturing pipeline, and expectations for revenue to surpass US$360 million by 2026 and potentially reach US$900 million by 2028 with improving EBITDA margins.
This evolution, occurring alongside continued insider share sales such as Director Barbara-jean Bormann-kennedy’s 15,000-share disposal on 12 December...